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PURPOSE. To determine whether moxifloxacin can be used
safely as an intraocular antibiotic, retinal safety of intravitreal
moxifloxacin was studied with electroretinography (ERG) and
histopathology in animal models.
METHODS. Moxifloxacin was injected into mouse eyes at intra-
vitreal concentrations of 5 to 500 g/mL and into rabbit eyes at
150 g/mL. As the control, the vehicle was injected into the
fellow eyes of each animal. Four weeks after injection, ERG
recordings were performed, and animal eyes were processed
for histologic examination.
RESULTS. ERG studies showed no significant difference between
control and moxifloxacin-injected eyes at any dose in either the
mouse or rabbit model. Histologic examination revealed no
retinal abnormality in mice at 5 to 100 g/mL or in rabbits at
150 g/mL intravitreal moxifloxacin. In mice at 500 g/mL,
occasional focal retinal necroses were observed, suggesting
isolated retinal toxicity at this concentration of moxifloxacin.
CONCLUSIONS. Intravitreal moxifloxacin, up to 100 g/mL in
mice or 150 g/mL in rabbits, caused no ERG or retinal histo-
logic abnormality. These results indicate that moxifloxacin is a
safe intravitreal antibiotic in mouse and rabbit animal models.
If proven safe and efficacious by further study in humans,
intravitreal injection of moxifloxacin could be considered as an
alternative to currently used antibiotics in selected patients
with resistance or allergy to the more traditional antibiotics.
(Invest Ophthalmol Vis Sci. 2006;47:1606 –1611) DOI:
10.1167/iovs.05-0702
Bacterial endophthalmitis is a devastating ocular disease thatcan lead to permanent blindness in a short time if not
treated properly and promptly. The Endophthalmitis Vitrec-
tomy Study (EVS) showed that after intraocular surgery such as
cataract extraction, 94% of culture-proven incidences of en-
dophthalmitis were due to Gram-positive bacteria, and only
approximately 6% were due to Gram-negative bacteria.1 The
treatment recommendations from the EVS for endophthalmitis
are vancomycin for Gram-positive bacteria and amikacin or
tobramycin for Gram-negative bacteria.2 Today, most cases of
endophthalmitis are treated with vancomycin and ceftazidime,
because amikacin and tobramycin have been reported to cause
retinal infarction, even at therapeutic concentrations.3 It
would be much more beneficial for the patients and more
convenient for ophthalmologists if only one antibiotic instead
of two could be used to treat both Gram-positive and Gram-
negative bacterial endophthalmitis.
Fluoroquinolone has been widely used in ophthalmology,
because of its broad Gram-positive and Gram-negative cover-
age.4–7 However, significant bacterial resistance to second- and
third-generation fluoroquinolone emerged in the mid-1990s.
For example, resistant strains causing bacterial keratitis in-
crease from 5% to 35% over a period of 4 years.8,9 The in vitro
susceptibility rates of Staphylococcus aureus, isolated from
patients with endophthalmitis, to ciprofloxacin, ofloxacin, and
levofloxacin decreased from 100% in 1993 to 0% in 2001.10
Moxifloxacin (Avelox; Bayer Pharmaceuticals Corp., West
Haven, CT), a fourth-generation fluoroquinolone, was initially
developed to treat Gram-positive bacterial respiratory infec-
tions.11–14 Unlike the second- and third-generation fluoro-
quinolones, which bind to only one of the two key enzymes
involved in bacterial DNA replication, moxifloxacin binds both
enzymes: bacterial DNA gyrase and topoisomerase IV.15,16
More extensive binding provides more effective bacterial kill-
ing and less bacterial mutation into resistant organisms. Thus,
moxifloxacin provides superior coverage against those Gram-
positive bacteria that were already resistant to the second- and
third-generation fluoroquinolones, and it also maintains excel-
lent coverage for Gram-negative bacteria.17 It has been dem-
onstrated that moxifloxacin’s minimum inhibitory concentra-
tion (MIC) and MIC90 (the concentration of drug causing a 90%
growth inhibition of organisms) are the lowest among all gen-
erations of fluoroquinolones, and its antibacterial activity is the
highest against the most common Gram-positive pathogens in
the EVS, such as coagulase negative Staphylococcus, S. aureus,
and Streptococcus pneumoniae.1
This experimental study was designed to examine whether
moxifloxacin can be safely used as an intravitreal agent in the
treatment of bacterial endophthalmitis in animal models. Intra-
vitreal injection of moxifloxacin was performed on mice and
rabbits, and retinal function and morphology were subse-




C57BL/6J mice 4 weeks of age (25 g) were obtained from the Charles
River Laboratories (Wilmington, MA). Mice were fed ad libitum with
laboratory chow (Purina, Richmond, IN) and water. Dutch Belted
rabbits weighing 2 to 2.5 kg were obtained from the Myrtle’s Rabbitry,
Inc. (Thompson Station, TN). The animals were housed in room light-
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ing with a 12-hour light–dark cycle. The experiments were performed
in accordance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research, and the protocol was approved by
the Institutional Review Board of Baylor College of Medicine.
Intravitreal Injection
Mice were anesthetized by intraperitoneal injection of a solution con-
taining ketamine (95 mg/mL) and xylazine (5 mg/mL) at a dose of 0.2
mL/100 g body weight. Proparacaine hydrochloride 0.5% (Alcon Lab-
oratories, Inc., Fort Worth, TX) was used for additional topical anes-
thesia. Ofloxacin ophthalmic solution 0.3% (Allergan Inc, Irvine, CA)
was applied to the ocular surface before injection, and bacitracin
ophthalmic ointment (E. Fougera & Co., Melville, NY) was applied
after injection, to prevent infection. Moxifloxacin, a white lyophilized
powder, was kindly provided by the Bayer Pharmaceuticals Corp.
(West Haven, CT). The minimum inhibitory concentration (MIC) of
moxifloxacin to bacterial keratitis isolates was found to be 0.016 to 4.0
g/mL.18 Because this is a retinal toxicity study, we chose to use 5
g/mL as a baseline concentration. Moxifloxacin solutions were seri-
ally diluted with sterile water as instructed by the manufacturer so that
the final intravitreal concentrations were 5, 25, 50, 100, and 500
g/mL based on an estimated adult mouse vitreous volume of 20 L.19
Serially diluted moxifloxacin solutions of 2 L were injected intravit-
really into mouse eyes under a dissecting microscope using a micro-
injector (Hamilton Co., Reno, NV). Five mice were used for each
concentration. A 30-gauge needle was first used to make a punch
incision 0.5 mm posterior to the temporal limbus, and the microinjec-
tor needle was then inserted through the incision, approximately 1.5
mm deep, angled toward the optic nerve until the tip of needle was
visualized in the center of the vitreous. Sterile water of the same
volume (2 L) was injected into the fellow eyes of each mouse as the
control. After injection, animals were kept in ambient light on a
12-hour light–dark schedule. Four weeks after injection, animals were
processed for electroretinogram (ERG) recordings and subsequent
retinal histology examinations.
Dutch Belted rabbits were also used, to examine the interspecies
difference and to confirm the experimental results in the mice. The
rabbits were anesthetized with an intramuscular injection of 0.5 mL/kg
body weight of a solution containing ketamine 42.8 mg, xylazine 8.6
mg, and acepromazine 1.4 mg/mL. Topical proparacaine hydrochlo-
ride was used for additional anesthesia, and ofloxacin and bacitracin
were also used to prevent infection. After anterior chamber paracen-
tesis, 200 g moxifloxacin in a volume of 0.1 mL was injected intrav-
itreally into the left eye of each rabbit. The injection was performed
with a 27-gauge needle through a site 2 mm posterior to the superior
limbus. A previous report showed that rabbit vitreous volume was 1.5
mL,20 but we measured vitreous volume in 27 adult rabbits and found
it to be 1.2 mL. Based on this measurement, the final intravitreal
concentration of moxifloxacin was approximately 150 g/mL, with
the concentration confirmed by HPLC (high pressure liquid chroma-
tography). Five rabbits were used. The fellow eye of each rabbit was
injected with 0.1 mL drug vehicle (water) as the control. After the
injection, the animals were kept for 4 weeks in ambient light on a
12-hour light/dark schedule. The rabbits were examined with indirect
ophthalmoscopy, and no retinal changes or detachments were noted
in any eye 4 weeks after the injections. ERGs were then performed
with subsequent retinal histology examinations.
ERG Recordings
The mice were placed in dark adaptation overnight before ERG testing.
In dim red light, mice were anesthetized with a solution of ketamine
and xylazine, as described earlier. Pupils were dilated with a single
drop of 0.5% tropicamide and 2.5% phenylephrine. A drop of 0.5%
proparacaine hydrochloride was applied for corneal anesthesia. The
mice were placed on a heating pad maintained at 39°C, inside a
Ganzfeld dome coated with highly reflective white paint (Munsell
Paint, New Windsor, NY). A small amount of 2.5% methylcellulose gel
was applied to the eye, and a platinum electrode was placed in contact
with the center of the cornea. Similar platinum reference and ground
electrodes were placed in the forehead and tail, respectively. After
placement in the dome, the mice were allowed to remain in complete
darkness for 5 minutes before the ERG was started. Signals were
amplified (P122 band-pass 0.1–1000 Hz; Grass-Telefactor, West War-
wick, RI). Data were then acquired at a sampling rate of 10,000 Hz
(DAQ board; National Instruments Laboratory; Austin, TX). Traces
were averaged and analyzed with custom software (written in MatLab;
The MathWorks, Natick, MA).
For ERGs in the rabbits, the test protocol was similar to that in the
mice. The rabbits were dark adapted for 1 hour, and 1 drop of 1%
tropicamide and 2.5% phenylephrine were instilled in the left eyes for
dilation. After 1 drop of hydroxypropyl methylcellulose (Goniosol;
Chiron Vision Ophthalmics) was instilled in the eye, a corneal contact
electrode (a contact electrode with gold foil; JET; LKC Technologies,
Gaithersburg, MD) was placed on the cornea. The reference electrode
was placed near the lid, and the ground electrode, in the scruff of the
neck. The ERG signals were amplified, and data were acquired as in the
mouse ERG test. Before intravitreal moxifloxacin injection, ERG was
performed as a baseline. Four weeks after the injection, ERG was
repeated on the same eyes.
Flashes were calibrated in a manner similar to that described pre-
viously21 and are described in detail elsewhere.22 Flashes for scotopic
measurements were generated by a photostimulator (model PS-33;
Grass-Telefector). Light was spectrally filtered with a 500-nm interfer-
ence filter (Edmund Industrial Optics, Barrington, NJ). A series of metal
plates with holes of various diameters and glass neutral-density filters
were used to attenuate the flash. Flashes varied in intensity from 3.85
to 0.76 log scotopic cd-s/m2. The scotopic b-wave was digitally
filtered using the “filtfilt ” function in the software (low pass filter, Fc
60 Hz ; MatLab; The MathWorks), to remove oscillatory potentials
before fitting. The relationship between b-wave amplitude and flash
intensity can be described by a saturating hyperbolic function (Naka-




where bmax,scot is the saturated scotopic b-wave amplitude, and I0.5 is
the intensity that provides half saturation. The baseline and peak of
each filtered trace was measured, and the data for multiple intensities
were fit to the equation.
For analysis of the a-wave and cone function, 1500-watt xenon flash
lamps (Novatron, Dallas, TX) were used to provide intense illumina-
tion, approximately 2.92 log scotopic cd-s/m2. To analyze the rod
function, we used the following equation (Lamb-Pugh model) to fit a




 exp12    A  t  teff2
where a(t) is the a-wave, amax is its saturating amplitude,  is the
number of photoisomerizations rod produced by the flash, A is the
amplification factor, and teff is a brief delay. Cone-driven responses
were recorded in the presence of a 540-nm rod-saturation background
light that measured 40 scotopic cd/m2 in intensity. The oscillatory
potentials were removed before measurement by digitally filtering the
cone driven b-wave with the filtfilt function in MatLab (low pass filter,
Fc 30 Hz). After removal of the oscillatory potentials, the peaks of the
b-wave (bmax,phot) and a-wave (amax,phot) were measured.
Retinal Histology
After ERG tests, mice were euthanatized with an overdose of intraperi-
toneal ketamine and xylazine, and rabbits were killed with a lethal
cardiac injection of Beuthanasia-D (Schering Plough Animal Health,
Omaha, NE). The animal eyes were then enucleated, a large full-
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thickness incision was made in the cornea, and the eye was fixed
immediately in 4% formaldehyde in 0.1 M phosphate buffer (pH 7.4).
After 15 minutes in the fixative, the lens was removed and the eye was
cut along the cornea-optic nerve axis into halves. Gross examinations
of the tissues were performed. Tissues were further fixed overnight in
4% paraformaldehyde and 0.5% glutaraldehyde in 0.1 M phosphate
buffer (pH 7.4). Tissues were then embedded in paraffin, sectioned at
a thickness of 6 m, and stained with hematoxylin and eosin. A light
microscope was used for histologic examinations.
RESULTS
Electroretinograms
ERG recordings from control and moxifloxacin-injected mouse
eyes are shown in Figure 1. Figure 1A shows scotopic b-wave
responses to increasing intensities of flashed light. The
scotopic b-wave is a measurement of the extracellular field
potential that primarily arises from rod bipolar cells in re-
sponse to dim flashes of light.23 The relationship between
scotopic b-wave amplitude and intensity can be modeled with
a hyperbolic saturation (Naka-Rushton) function. This model
yields two parameters, bmax,scot and I0.5, representing the max-
imum b-wave amplitude and the intensity that provides half
saturation, respectively. As shown in Figure 1A, scotopic re-
cordings from control eyes demonstrated a progressive in-
crease in b-wave amplitude with increasing intensity of light.
The maximum b-wave amplitude in control eyes was 530  55
V and the half-saturation intensity measured 1.9  0.2 /rod.
The b-waves measured from eyes injected with various con-
centrations of moxifloxacin demonstrate similar morphology
and amplitude. There was no statistically significant difference
in bmax,scot or I0.5 between control eyes and any of the groups
of moxifloxacin-injected eyes (Table 1). Significance was mea-
sured with both the Student’s t-test (two-tailed, assuming
equal variance) and ANOVA. Figure 1B shows the ERG
response to an intense flash that saturates the rod photore-
ceptors. The saturated scotopic a-wave from control eyes
measured 690  25 V. Once again, there was no significant
difference between control eyes and those injected with
moxifloxacin (Table 1). To determine cone function, pho-
topic ERGs were measured in the presence of a rod-satura-
tion background (Fig. 1C). For control eyes, bmax,phot mea-
sured 190  40 V and amax,phot measured 75  15 V.
Again, there was no significant difference in the photopic
response measured from control eyes and moxifloxacin-
injected eyes (Table 1).
FIGURE 1. ERG recordings from mouse
eyes injected with various concentra-
tions of intravitreal moxifloxacin (5,
50, and 500 g/mL) or drug vehicle
as the control. (A) Scotopic record-
ings demonstrated a progressive in-
crease in b-wave amplitude with in-
creasing intensity of light. b-Waves
measured from the control eyes and
moxifloxacin-injected eyes showed
very similar morphology and ampli-
tude. (B) ERG response to an intense
flash that saturates the rod photore-
ceptors. The saturated scotopic a-waves
from control eyes and moxifloxacin-
injected eyes show no significant dif-
ference. To measure cone function,
photopic ERG was recorded in the
presence of a rod-saturation back-
ground (C). Again, there was no sig-
nificant difference in the photopic
responses measured from control
eyes and moxifloxacin-injected eyes
(see Table 1 for detailed data).
TABLE 1. ERG Data of Mouse Eyes with Various Intravitreal Concentrations of Moxifloxacin
Dose bmax,scot (V) I0.5 (/rod) amax,scot (V) bmax,phot (V) amax,phot (V)
Control (n  4) 530  55 1.9  0.2 690  25 190  40 (n  3) 75  15
5 g/mL (n  4) 430  30 1.8  0.1 550  45 230  10 (n  4) 65  10
50 g/mL (n  4) 575  35 2.6  0.4 590  20 210  50 (n  3) 50  10
500 g/mL (n  5) 505  25 2.0  0.01 630  35 270  25 (n  5) 55  10
Concentration is the intravitreal concentration of moxifloxacin. Control is the eyes injected with the
drug vehicle, which was water. bmax,scot is the maximum b-wave amplitude in scotopic condition, I0.5, the
flash intensity that provides half saturation, and amax,scot, the maximum a-wave amplitude. bmax,phot and
amax,phot are the maximum b-wave amplitude and maximum a-wave amplitude, respectively, in photopic
stimulation.
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Similarly, ERG recordings were performed in rabbit eyes
before and 4 weeks after moxifloxacin injection. Scotopic
b-wave responses to increasing intensities of flashed light (Fig.
2A), saturated scotopic a-wave (Fig. 2B), and photopic record-
ings (Fig. 2C) were measured before (left) and after (right)
moxifloxacin injection. Scotopic bmax was 397  54 and 408 
23 V, and I0.5 was 9.4  0.6 and 9.1  0.7 /rod, before and
after moxifloxacin injection, respectively. Scotopic amax was
199  17 and 177  54 V; photopic bmax was 192  12 and
177  13 V, and photopic amax was 94  5 and 85  3
V, before and after moxifloxacin injection, respectively.
Again, statistical analysis showed no significant difference be-
tween the pre- and postinjection groups in any of the scotopic
or photopic recordings (Fig. 2). Thus, ERG studies show no
evidence of retinal functional change in either the mouse or
rabbit model after intravitreal moxifloxacin injection of any
concentration groups tested in this study.
Retinal Histology
Gross examination of eye specimens showed no evidence of
retinal detachment, retinal hemorrhages, or signs of infection
in any moxifloxacin injected or control eyes in either mice or
rabbits. Two mouse lenses were found to be opacified after
intravitreal injection, probably due to needle injury, and these
two eyes were excluded from the study. Four rabbit lenses
were noted to have focal peripheral opacities after intravitreal
injection. These eyes were included in the study, since the lens
opacity was small and located in the periphery, and the ERG
data from these eyes were in the range of the other eyes
without lens injury. A small vitreous hemorrhage was noted in
the inferior periphery of one rabbit eye, but no retinal detach-
ment or retinal hemorrhage was detected. This eye was also
included in the study, since the ERG data were in the range of
data in the other eyes.
Histologic examination with light microscopy did not reveal
any retinal abnormality in the mouse or rabbit control eyes
injected with drug vehicle (images not shown). In the mouse
eyes with intravitreal moxifloxacin from 5.0 to 100 g/mL, no
retinal abnormality was observed in any retinal area (Fig. 3A).
In the mouse eyes with 500 g/mL intravitreal moxifloxacin,
very small focal retinal necroses were occasionally noted in the
retina (Fig. 3B). In these necrotic areas, the photoreceptor
layer was disorganized. Photoreceptor degeneration was evi-
dent, and photoreceptor inner and outer segments were ab-
sent. The inner nuclear layer also showed a mild degenerative
change. The ganglion cell layer appeared intact. In the areas
where focal necrosis was not observed, the retina was normal
in light microscopy examination. In the rabbit eyes with 150
g/mL intravitreal moxifloxacin, histologic examination
showed completely normal retinas with no evidence of retina
necrosis in any area (Fig. 4).
DISCUSSION
This study shows that moxifloxacin did not display retinal
toxicity when examined by ERG or histology, when the intra-
FIGURE 2. ERG recordings from rabbit eyes before (left) and 4 weeks
after (right) moxifloxacin injection. (A) Scotopic b-wave responses to
increasing intensities of flashed light and (B) saturated scotopic a-wave
and (C) photopic recordings. Statistical analysis shows no significant
difference between pre- and postinjection groups in any of these either
scotopic or photopic recordings.
FIGURE 3. Retinal histology of mouse eyes with intravitreal injection
of moxifloxacin. (A) In the mouse eyes with intravitreal moxifloxacin
from 5.0 o 100 g/mL, no retinal abnormality was observed in any
retinal area. The retinal detachment is an artifact of tissue processing.
(B) In the eyes injected with 500 g/mL intravitreal moxifloxacin, very
small focal retinal necroses were occasionally noted in the retina. In
these necrotic areas, the photoreceptor layer was disorganized. Pho-
toreceptor degeneration was evident, and the inner and outer seg-
ments were absent. The inner nuclear layer also showed mild degen-
erative change. ONL, outer nuclear layer; INL, inner nuclear layer; GCL,
ganglion cell layer. Scale bar, 100 m.
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vitreal concentration was 100 g/mL or less in the mice or 150
g/mL in the rabbits. When the concentration reached 500
g/mL in the mice, very slight focal retinal necrosis was occa-
sionally noted on histologic examination, but ERG was not
affected. This finding is to be expected, as ERG is a mass
electrical response from the entire retina, and focal necrosis
would not be expected to cause ERG abnormality. The possible
species difference was reduced to a minimum, since two spe-
cies were examined in our study and revealed very similar
intravitreal moxifloxacin levels without retinal toxicity. When
these results are extrapolated to humans, moxifloxacin of 400
to 500 g may be safely injected intravitreally in the eyes
without causing ERG or histologic abnormalities, based on the
fact that average human vitreous volume is 4 mL. However,
further study in human eyes is needed to determine the safe
intravitreal moxifloxacin dosage.
Hariprasad et al.24 studied intraocular penetration of topical
0.5% moxifloxacin ophthalmic agent (Vigamox; Alcon Labora-
tories, Inc.) in 20 patients. They found that the average moxi-
floxacin aqueous and vitreous concentrations were 2.28 and
0.11 g/mL, respectively, if the eye drops were given every 2
hours for 3 days, and were 0.88 and 0.06 g/mL, respectively,
if given every 6 hours. Although MIC90 was exceeded in the
aqueous for a wide spectrum of pathogens, intravitreal con-
centration of moxifloxacin was too low for many organisms.24
We also studied intraocular penetration of systemic moxifloxa-
cin in 15 patients.25 The average intravitreal and intracameral
moxifloxacin concentrations were 1.34  0.66 and 1.58 
0.80 g/mL, respectively. Compared with topical moxifloxa-
cin, oral moxifloxacin results in a 10-times higher intravitreal
concentration. MIC90 levels were achieved in the vitreous and
aqueous against a wide spectrum of pathogens, such as S.
epidermidis, S. aureus, S. pneumoniae, S. pyogenes, Propi-
onibacterium acnes, Haemophilus influenzae, and Bacillus
cereus, the most common endophthalmitis-causing organisms.
However, the intravitreal or intracameral level achieved by oral
moxifloxacin in this study does not exceed the MICs of fluo-
roquinolone-resistant strains, especially coagulase negative
Staphylococcus and S. aureus, the most common organisms
causing endophthalmitis.
As described in the introduction, bacterial resistance to
prior-generation fluoroquinolones has increased significantly
since the mid-1990s.8–10,26 Based on a study of 93 bacterial
endophthalmitis isolates, mean moxifloxacin MICs for fluoro-
quinolone-susceptible coagulase negative Staphylococcus and
S. aureus were only 0.05 and 0.06 g/mL, but they were 2.5
g/mL and 1.75 g/mL, respectively, for fluoroquinolone-re-
sistant coagulase negative Staphylococcus and S. aureus.27 In
another study of 177 bacterial keratitis isolates, moxifloxacin’s
MIC90 was as high as 3.0 and 4.0 g/mL for fluoroquinolone-
resistant coagulase negative Staphylococcus and S. aureus,
respectively.18 Thus, susceptibility to moxifloxacin was only
50% to 60%27 or 76% (Rosenberg KD et al. IOVS 2004;45:ARVO
E-Abstract 509) for fluoroquinolone-resistant coagulase nega-
tive Staphylococcus isolated from patients with endophthalmi-
tis. Oral moxifloxacin cannot achieve sufficient intravitreal and
intracameral levels for fluoroquinolone-resistant Staphylococ-
cus. Intravitreal injection of 400 g moxifloxacin in the human
eye, which results in an intravitreal concentration of 100 g/
mL, would be sufficient to cover all fluoroquinolone-resistant
staphylococci.
Thus, if proven safe and efficacious by further study in
humans, intravitreal injection of moxifloxacin could be consid-
ered an alternative to currently used antibiotics in selected
patients with resistant bacterial infection or allergy to the more
traditional antibiotics.
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